Medication Development for the Treatment of Cocaine Dependence: Issues in Clinical Efficacy Trials

Editors:

Betty Tai, Ph.D.

Nora Chiang, Ph.D.

Peter Bridge, M.D.

NIDA Research Monograph 175 1997

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES **National Institutes of Health**

National Institute on Drug Abuse Office of Science Policy and Communications 5600 Fishers Lane Rockville, MD 20857

ACKNOWLEDGMENT

This monograph is based on the papers from a technical review "Medication Development for the Treatment of Cocaine Dependence: Issues in Clinical Efficacy Trials" held on October 20-21, 1994. The review meeting was sponsored by the National Institute on Drug Abuse.

COPYRIGHT STATUS

The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder's permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated.

Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services.

The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein.

National Institute on Drug Abuse NIH Publication No. 97-4125 Printed 1997

NIDA Research Monographs are indexed in the *Index Medicus*. They are selectively included in the coverage of *American Statistics Index*, *BioSciences Information Service*, *Chemical Abstracts*, *Current Contents*, *Psychological Abstracts*, and *Psychopharmacology Abstracts*.

Table of Contents

Click on title or page number to go to section

Preface
Goals and Rationale for Pharmacotherapeutic Approach n Treating Cocaine Dependence: Insights From Basic and Clinical Research
Overview of Potential Treatment Medications for Cocaine Dependence
Methodologic Recommendations for Cocaine Abuse Clinical Frials: A Clinician-Researcher's Perspective
Management of Clinical Trials With New Medications for Cocaine Dependence and Abuse96 Ari Kiev
Outcome Measurement Considerations: Pharmacological Freatments for Substance Abuse
Variability in Treatment-Seeking Cocaine Abusers: Implications for Clinical Pharmacotherapy Trials
Baseline Assessment, Study Entry, and Stabilization: Double-Blind Clinical Trials in Drug Dependence
The Addiction Severity Index in Clinical Efficacy Trials of Medications for Cocaine Dependence

Cognitive-Neuromotor Assessment of Substance Abuse: Focus on Issues Related to Cocaine Abuse Treatment192 E.H. Ellinwood, Jr. and T.H. Lee
Treatment Effectiveness Score as an Outcome Measure in Clinical Trials
Pharmacokinetics of Cocaine: Considerations When Assessing Cocaine Use by Urinalysis
Quantitative Urine Levels of Cocaine and Other Substances of Abuse
Use of Quantitative Urinalysis in Monitoring Cocaine Use253 Kenzie L. Preston, Kenneth Silverman, Charles R. Schuster, and Edward J. Cone
Is Quantitative Urinalysis More Sensitive?265 Shou-Hua Li, Nora Chiang, Betty Tai, Charles K. Marschke, and Richard L. Hawks
Comparison of Immunoassays for Semiquantitative Measurement of Benzoylecgonine in Urine
Appendix I: Workshop Summary Outcome Measures and Success Criteria
Appendix II: Workshop Summary Clinical Decision Tree for Cocaine Addiction Pharmacotherapy